Sequence | Number of participants | Study period |
---|
1 | 2 | 3 | 4 |
---|
1
| 4 | B | D | B | C |
2
| 4 | B | B | C | D |
3
| 4 | C | B | D | B |
4
| 4 | D | C | B | B |
5
| 12 | A | C | A | C |
6
| 12 | C | A | C | A |
7
| 12 | A | C | C | A |
8
| 12 | C | A | A | C |
- A: PF-03654764 capsule (5 mg) + fexofenadine capsule (60 mg) + placebo capsule.
- B: PF-03654764 capsule (5 mg) + placebo capsule + placebo capsule.
- C: placebo capsule + placebo capsule + fexofenadine (60 mg)/pseudoephedrine (120 mg) capsule.
- D: placebo capsule + placebo capsule + placebo capsule.